Tecnología del ADN recombinante en el diagnóstico clínico del Covid-19

Abstract

The development of recombinant DNA technology has provided us with a set of techniques to identify and characterize genes from different sources in a new combination and their propagation or expression in a host, giving rise to recombinant proteins that allow us to obtain information for diagnosis. clinic of various pathologies such as Covid-19. Objective: To correlate the role of the biochemist in the technological applications of recombinant DNA in COVID-19 through a brief collection of scientific data that allows the professional to better use the tools that benefit clinical diagnosis. Methodology: descriptive, analytical method based on the review of bibliographic sources of scientific articles, indexed in scopus, science direct, scielo that allows us to analyze recombinant technology and the performance of the pharmaceutical biochemist in the laboratory in times of the pandemic. Result: Advances in recombinant DNA technology allow us to identify and obtain the sequence of genes, and establish their role in the clinical diagnosis of various pathologies such as Covid-19 with the help of the transcription polymerase chain reaction technique. inverse with real-time amplification (RT-PCR), which is considered the method with the highest accuracy thanks to the recognition of the recombinant proteins of SARS-CoV-2. Pharmaceutical biochemists in the clinical laboratory provide critical information to clinicians about prognosis, disease course, and response to therapy, as well as participate in quality control to generate reliable and accurate results that correlate to biological reference intervals.